Please login to the form below

Not currently logged in
Email:
Password:

MSD strikes vernakalant deal with Astellas

US-based pharmaceutical company MSD has acquired the rights for heart drug vernakalant from Astellas

MSD (known as Merck in the US and Canada) has acquired the exclusive rights to develop and commercialise the investigational intravenous formulation of atrial fibrillation drug vernakalant in Canada, Mexico and the US from Astellas.

MSD will pay Astellas an undisclosed upfront fee. In addition, Astellas will be eligible for milestone payments associated with development and regulatory approval, as well as sales thresholds achieved in Canada, Mexico and the US.

Masao Yoshida, president and chief executive of Astellas US, said: "In reviewing the priorities of our North American development programmes, Astellas has decided to divest its rights for vernakalant to Merck."

In October 2003, Astellas US was granted an exclusive licence to develop and commercialise vernakalant iv in Canada, Mexico and the US by Cardiome Pharma Corp. In April 2009, MSD, through a subsidiary, was granted exclusive rights to vernakalant iv outside of Canada, Mexico and the US for rapid conversion of acute atrial fibrillation to normal heart rhythm.

Vernakalant is approved in more than 10 European countries.

27th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Running
A marathon and a sprint
Customer experience is a long-distance race and with pharma late out of the blocks, companies need to put their foot down if they want to compete...
5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...
Finding the patient voice
How patients feel and speak about clinical trials...

Infographics